echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovative drugs introduced by CMS for the treatment of psoriasis are planned to be included in the priority review

    Innovative drugs introduced by CMS for the treatment of psoriasis are planned to be included in the priority review

    • Last Update: 2022-01-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ArticleMedicine Guanlan

    According to the latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China, the methotrexate injection (prefilled) introduced by CMS is based on “the innovation of urgently needed clinically-needed drugs, imitation of key infectious diseases, rare diseases and other diseases.


    Screenshot source: CDE official website

    According to an earlier press release issued by CMS, methotrexate (MTX) is the first-line standard for systemic treatment of rheumatoid arthritis (RA), but oral methotrexate has greater gastrointestinal side effects and patients comply with it.


    According to reports, the methotrexate prefilled syringe/injection pen (MTX-medac) is a low-dose and small-volume methotrexate injection of various specifications, allowing patients to self-administer subcutaneously


    Previously, MTX-medac has been approved in Europe and the United States for the treatment of rheumatoid arthritis and other autoimmune diseases, such as polyarticular juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, Crohn Graciousness and so on


    In June of this year, CMS received a drug clinical trial approval notice issued by NMPA, and agreed to MTX-medac to carry out clinical trials for adult rheumatoid arthritis indications


    The MTX-medac is planned to be included in the priority review, and the indication is psoriasis


    CMS recently pointed out in a press release that MTX-medac has been announced as a reference preparation (RLD) by China’s National Food and Drug Administration, and is expected to become China’s first subcutaneously administered methotrexate drug to treat psoriasis.


    references:

    [1] Center for Drug Evaluation (CDE) of China National Medical Products Administration.


    [3] CMS and medac signed a license agreement for standard treatment products for the treatment of autoimmune diseases and bladder cancer.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.